慢性心力衰竭患者血浆cMyBP-C水平的变化

李源繁, 杨国杰, 李栋博, 等. 慢性心力衰竭患者血浆cMyBP-C水平的变化[J]. 临床心血管病杂志, 2020, 36(8): 755-759. doi: 10.13201/j.issn.1001-1439.2020.08.016
引用本文: 李源繁, 杨国杰, 李栋博, 等. 慢性心力衰竭患者血浆cMyBP-C水平的变化[J]. 临床心血管病杂志, 2020, 36(8): 755-759. doi: 10.13201/j.issn.1001-1439.2020.08.016
LI Yuanfan, YANG Guojie, LI Dongbo, et al. Changes of plasma cMyBP-C level in patients with chronic heart failure[J]. J Clin Cardiol, 2020, 36(8): 755-759. doi: 10.13201/j.issn.1001-1439.2020.08.016
Citation: LI Yuanfan, YANG Guojie, LI Dongbo, et al. Changes of plasma cMyBP-C level in patients with chronic heart failure[J]. J Clin Cardiol, 2020, 36(8): 755-759. doi: 10.13201/j.issn.1001-1439.2020.08.016

慢性心力衰竭患者血浆cMyBP-C水平的变化

  • 基金项目:

    河南省科技计划(科技攻关)项目(No:182102310639)

详细信息
    通讯作者: 杨国杰,E-mail:yang63315@126.com
  • 中图分类号: R541.6

Changes of plasma cMyBP-C level in patients with chronic heart failure

More Information
  • 目的:探讨慢性心力衰竭(CHF)患者血浆中心脏型肌球蛋白结合蛋白-C(cMyBP-C)水平变化及其对近期预后的预测价值。方法:选取89例新入院确诊为CHF的患者为CHF组,30名健康体检者为对照组。收集所有受试者入院时及CHF组治疗1个月后的血浆样本,检测其cMyBP-C水平。彩色多普勒超声心动图仪检测左心室射血分数(LVEF)、左心室短轴缩短率(LVFS)及E/A比值等。对cMyBP-C与心力衰竭指标进行相关性分析。对CHF组进行为期12个月的临床随访,记录主要不良心血管事件(MACE)的发生情况。用COX回归分析并绘制ROC曲线评价血浆cMyBP-C表达水平对CHF近期预后的预测价值。结果:CHF组患者入院时cMyBP-C血浆水平较对照组入院时明显升高[(137.07±44.44) ng/ml∶(29.29±10.37) ng/ml,P<0.01];CHF组患者治疗1个月后与入院时相比较明显降低[(84.67±37.98) ng/ml∶(137.07±44.44) ng/ml,P<0.01]。Pearson相关分析显示,CHF患者入院时血浆cMyBP-C水平与B型脑钠肽前体(proBNP)呈正相关性(r=0.711,P<0.01),与LVEF、LVFS、E/A比值均呈负相关性(r=-0.659、-0.457、-0.478,均P<0.01)。Spearman相关性分析显示,CHF患者入院时血浆cMyBP-C水平与NYHA分级呈正相关性(r=0.756,P<0.01)。Cox回归分析结果显示,入院时血浆cMyBP-C水平是近期发生MACE的独立危险因素(HR=1.024,95%CI:1.001~1.048,P=0.044)。ROC结果显示,入院时血浆cMyBP-C水平预测CHF患者近期发生MACE的曲线下面积为0.805(95%CI:0.688~0.922),截点值为154.71 ng/ml,灵敏度为84.2%,特异度为74.1%。结论:cMyBP-C在CHF患者血浆中的表达水平可能发生改变,可为预测患者近期内MACE的发生风险提供参考。
  • 加载中
  • [1]

    Abi-Samra F,Gutterman D.Cardiac contractility modulation:a novel approach for the treatment of heart failure[J].Heart Fail Rev,2016,21(6):645-660.

    [2]

    Berezin AE,Kremzer AA,Martovitskaya YV,et al.The utility of biomarker risk prediction score in patients with chronic heart failure[J].Clin Hypert,2015,22:3.

    [3]

    Sadayappan S,De Tombe PP.Cardiac myosin binding protein-C as a central target of cardiac sarcomere signaling:A special mini review series[J].Pflugers Arch,2014,466(2):195-200.

    [4]

    Kaier TE,Twerenbold R,Puelacher C,et al.Direct comparison of cardiac myosin-binding protein c to cardiac troponins for the early diagnosis of acute myocardial infarction[J].Circulation,2017,136(16):1495-1508.

    [5]

    Govindan S,Kuster DW,Lin B,et al.Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction[J].Am J Cardiovasc Dis,2013,3(2):60-70.

    [6]

    De Lange WJ,Grimes AC,Hegge LF,et al.E258K HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction[J].J Gen Physiol,2013,142(3):241-255.

    [7]

    中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.

    [8]

    Sato Y,Fujiwara H,Takatsu Y.Biochemical markers in heart failure[J].J Cardiol,2012,59(1):1-7.

    [9]

    Previs MJ,Prosser BL,Mun JY,et al.Myosin-binding protein C corrects an intrinsic inhomogeneity in cardiac excitation-contraction coupling[J].Sci Adv,2015,1(1):e1400205.

    [10]

    Kensler RW,Craig R,Moss RL.Phosphorylation of cardiac myosin binding protein C releases myosin heads from the surface of cardiac thick filaments[J].Proc Natl Acad Sci U S A,2017,114(8):E1355-E1364.

    [11]

    Jacques AM,Copeland O,Messer AE,et al.Myosin binding protein C phosphorylation in normal,hypertrophic and failing human heart muscle[J].J Mol Cell Cardiol,2008,45(2):209-216.

    [12]

    Copeland O,Sadayappan S,Messer AE,et al.Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle[J].J Mol Cell Cardiol,2010,49(6):1003-1011.

    [13]

    Tong CW,Dusio GF,Govindan S,et al.Usefulness of released cardiac myosin binding protein-C as a predictor of cardiovascular events[J].Am J Cardiol,2017,120(9):1501-1507.

    [14]

    El Amrousy D,Hodeib H,Suliman G,et al.Diagnostic and prognostic value of plasma levels of cardiac myosin binding protein-C as a novel biomarker in heart failure[J].Pediatr Cardiol,2017,38(2):418-424.

    [15]

    Sadayappan S.Cardiac myosin binding protein-C:a potential early-stage,cardiac-specific biomarker of ischemia-reperfusion injury[J].Biomark Med,2012,6(1):69-72.

    [16]

    Razzaque MA,Gupta M,Osinska H,et al.An endogenously produced fragment of cardiac myosin-binding protein C is pathogenic and can lead to heart failure[J].Circ Res,2013,113(5):553-561.

    [17]

    Govindan S,Sarkey J,Ji X,et al.Pathogenic properties of the N-terminal region of cardiac myosin binding protein-C in vitro[J].J Muscle Res Cell Motil,2012,33(1):17-30.

  • 加载中
计量
  • 文章访问数:  182
  • PDF下载数:  42
  • 施引文献:  0
出版历程
收稿日期:  2020-04-10
修回日期:  2020-04-30

目录